Which criteria of choice to protect patients against thromboembolic events?

Organized with the participation of Alliance BMS/Pfizer

Jeudi 18 Janvier 2018   14:00-15:30   Maillot room
Symposium (organized with the participation of Industry)
14:00 • Maxime Guenoun
From clinical case to efficiency: initiation and switch
In drug development
14:30 • Nicolas Meneveau
In the treatment of pulmonary embolism
14:45 • Olivier Piot
In dosage choice for treating atrial fibrillation
15:00
Debate